Original article:

HISTOLOGICAL AND TOXICOLOGICAL EVALUATION, IN RAT, OF A P-GLYCOPROTEIN INDUCER AND ACTIVATOR: 1-(PROPAN-2-YLAMINO)-4-PROPOXY-9H-THIOXANTHEN-9-ONE (TX5)

Carolina Rocha-Pereira1*, Vera Silva1, Vera Marisa Costa1, Renata Silva1, Juliana Garcia2, Salomé Gonçalves-Monteiro3, Margarida Duarte-Araújo4, Alice Santos-Silva5, Susana Coimbra5,6, Ricardo Jorge Dinis-Oliveira1,6,7, Catarina Lopes8, Paula Silva9, Solida Long10, Emília Sousa10, Maria de Lourdes Bastos1, Fernando Remião1*

1 UCIBIO/REQUI-MTE, Laboratório de Toxicologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal
2 CITAB – Centre for the Research and Technology of Agro-Environmental and Biological Sciences, Department of Agronomy, University of Trás-os-Montes e Alto Douro, 5001-801 Vila Real, Portugal
3 LAQV/REQUI-MTE, Laboratório de Farmacologia, Departamento de Ciências do Medicamento, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal
4 LAQV/REQUI-MTE, Departamento de Imuno-Fisiologia e Farmacologia, Instituto de Ciências Biomédicas de Abel Salazar (ICBAS), Universidade do Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal
5 UCIBIO/REQUI-MTE, Laboratório de Bioquímica, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal
6 Instituto de Investigação e Formação Avançada em Ciências e Tecnologias Saúde (IINFACTS), Departamento de Ciências, Instituto Universitário de Ciências da Saúde (IUCS-CESP), Rua Central de Gandra, 1317, 4585-116 Gandra, Portugal
7 Departamento de Saúde Pública e Ciências Forenses e Educação Médica, Faculdade de Medicina, Universidade do Porto, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
8 Molecular Oncology and Viral Pathology Group, Centro de Investigação do IPO-Porto
9 Departamento de Microscopia, Laboratório de Histologia e Embriologia, Instituto de Ciências Biomédicas de Abel Salazar (ICBAS), Universidade do Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal
10 CIIMAR, Laboratório de Química Orgânica e Farmacêutica, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal

* Corresponding authors: Carolina Rocha-Pereira (mcamorim@ff.up.pt) and Fernando Remião (remino@ff.up.pt), UCIBIO/REQUI-MTE, Laboratório de Toxicologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal

http://dx.doi.org/10.17179/excli2019-1675

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/).
ABSTRACT

P-glycoprotein (P-gp) is an ATP-binding cassette transporter involved in the efflux of numerous compounds that influences the pharmacokinetics of xenobiotics. It reduces intestinal absorption and exposure of target cells to toxicity. Thioxanthones are compounds able to induce and/or activate P-gp in vitro. Particularly, 1-(propan-2-ylamino)-4-propoxy-9H-thioxanthen-9-one (TX5) behaves as a P-gp inducer and activator in vitro. The aims of this study were: i) to perform a histological characterization, by testing a single high dose of TX5 [30 mg/kg, body weight (b.w.), gavage], administered to Wistar Han rats, 24 hours after administration; and ii) to perform both a complete histological characterization and a preliminary safety evaluation, in distinct target organs, 24 hours after administration of a single lower dose of TX5 (10 mg/kg, b.w., gavage) to Wistar Han rats. The results showed a relevant histological toxicity for the higher dose of TX5 administered (30 mg/kg, b.w.), manifested by extensive hepatic necrosis and splenic toxicity (parenchyma with hyperemia, increased volume of both white and red pulp, increased follicles marginal zone). Moreover, in the kidneys, a slight hyperemia and tubular edema were observed in TX5-treated animals, as well as an inflammation of the small intestine. On the contrary, for the lower tested dose (10 mg/kg, b.w.), we did not observe any relevant histological toxicity in the evaluated organs. Additionally, no significant differences were found in the ATP levels between TX5-exposed and control animals in any of the evaluated organs, with the exception of the intestine, where ATP levels were significantly higher in TX5-treated rats. Similarly, TX5 caused a significant increase in the ratio GSH/GSSG only in the lungs. TX5 (10 mg/kg, b.w.) did not induce any change in any of the hematological and biochemical circulating evaluated parameters. However, TX5 was able to significantly reduce the activated partial thromboplastin time, without affecting the prothrombin time. The urine biochemical analysis revealed a TX5-mediated increase in both creatinine and sodium. Taken together, our results show that TX5, at a dose of 10 mg/kg, does not induce considerable toxicity in the biological matrices studied. Given this adequate safety profile, TX5 becomes a particularly interesting compound for ex vivo and in vivo studies, regarding the potential for induction and activation of P-gp at the intestinal barrier.

Keywords: Thioxanthones, oxidative stress, P-glycoprotein, toxicological biomarkers, peripheral toxicity

Graphical abstract
INTRODUCTION

Thioxanthones (TXs) are heterocyclic compounds with several reported biological activities and therapeutic potential, namely those related to antitumor activity and P-glycoprotein (P-gp) modulation potential (Paiva et al., 2013). ATP-binding cassette (ABC) carriers are efflux pumps mainly located at the plasma membrane of barrier tissues, such as the intestine, where they affect the pharmacokinetics of both endobiotics and xenobiotics. For this reason, ABC proteins are involved in the multidrug resistance (MDR) phenomenon, being responsible for the extrusion of many unrelated therapeutically important drugs, including anticancer agents. On the other hand, ABC proteins, due to their efflux function, are important to maintain cellular homeostasis and to detoxify potentially toxic substances by avoiding their accumulation inside the cells (DeGorter et al., 2012; Silva et al., 2015b). P-gp belongs to the ABCB subfamily of carriers and is one of the most studied ABC proteins, being involved in drug efficacy and toxicity. Given the involvement of ABC carriers, particularly P-gp, in the defense mechanism against toxic substances, as well as in the MDR phenotype, they play a relevant role in physiological, pharmacological and toxicological fields (Couture et al., 2006; Silva et al., 2015b). As such, there is much interest in modulating ABC efflux function. Compounds interacting with ABC transporters can act as substrates, inhibitors, inducers or activators, but one compound can also have overlapping modes of action (Gameiro et al., 2017; Wessler et al., 2013). Several in vitro and in vivo studies have shown that both the expression levels and the activity of ABC transporters can be modulated by inducers (Dinis-Oliveira et al., 2006; Silva et al., 2011; Silva et al., 2013) and activators (Martins et al., 2019; Silva et al., 2015a; Silva et al., 2014; Vilas-Boas et al., 2013). The inducing and activating effects have been shown to be triggered by (thio)xanthonic compounds, protecting different cell models against paraquat-mediated toxicity (Martins et al., 2019; Silva et al., 2015a; Silva et al., 2014; Vilas-Boas et al., 2013). The inducing and activating effects have been shown to be triggered by (thio)xanthonic compounds, protecting different cell models against paraquat-mediated toxicity (Martins et al., 2019; Silva et al., 2015a; Silva et al., 2014). Particularly, Silva and co-authors (Silva et al., 2015a) tested five newly synthesized thioxanthonic derivatives (TX1-5) in Caco-2 cells, observing that all examined compounds were able to promote both the induction and the activation of P-gp, although with a significantly more pronounced...
effect for TX5, with consequent lower cytotoxicity effects elicited by paraquat (Silva et al., 2015a). Our research group is committed to continue this line of research, aiming at finding P-gp inducers and/or activators at the intestine, with an adequate safety/efficacy relationship, using ex vivo and in vivo methodologies, in order to find enhancers of safety of xenobiotics. In this regard, TX5 showed to behave as a P-gp activator in the rat ileum (data submitted for publication). To accomplish our purpose, a first histological and toxicological evaluation of TX5 was performed, herein presented, testing two different doses administered to Wistar Han rats and selecting the less toxic dose to be used in the functional studies.

MATERIALS AND METHODS

Chemicals and drugs
TX5 hydrochloride was synthesized by the Organic and Pharmaceutical Chemistry Laboratory of the Faculty of Pharmacy of University of Porto, according to described procedures (Palmeira et al., 2012). Briefly, a copper-catalyzed (CuI) cross-coupling between 1-chloro-4-propoxy-9H-thioxanthen-9-one and isobutylamine, in alkaline medium (K2CO3) and methanol, using a closed vessel and conventional heating (100 °C), was performed. TX5 was characterized by spectroscopic methods and data was in accordance to described procedures (Palmeira et al., 2012). The purity of the compound was determined by HPLC-DAD analysis, yielding a high degree of purity of at least 95 %. Bovine serum albumin (BSA), glycine, Tris hydrochloride, reduced glutathione (GSH), oxidized glutathione (GSSG), glutathione reductase (GR), 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB), adenosine triphosphate (ATP), luciferase, D-luciferin, 2-vinylpyridine were all obtained from Sigma-Aldrich (Saint Louis, MI/USA). Folin-Ciocalteu reagent, copper (II) sulphate, perchloric acid (HClO4), ethylenediaminetetraacetic acid (EDTA), potassium bicarbonate (KHCO3), sodium hydroxide (NaOH), sodium carbonate, disodium phosphate, magnesium sulphate and potassium dihydrogen phosphate were purchased from Merck (Darmstadt, Germany). Potassium sodium tartrate was purchased from Fluka (Buchs SG, Switzerland). Sodium phosphate monobasic and reduced β-nicotinamide phosphate adenine dinucleotide (β-NADPH) were obtained from Panreac (Barcelona, Spain). Sodium chloride was purchased from VWR. Xylazine and ketamine were obtained from Novavet (Bragança, Portugal) and heparin from Braun (Germany). Isoflurane (Isoflo®) was purchased from Abbott (IL, USA). For histopathological analysis, commercial 4 % buffered formalin was acquired from Klinipath (Netherlands), while ethanol was purchased from Panreac AppliChem (Darmstadt, Germany), xylene from BDH – Prolabo, VWR International (Ireland), and paraffin from Merck (Germany). Chemicals for hematoxylin-eosin (H&E) and periodic acid-schiff (PAS)/Alcian Blue stains were obtained from Sigma-Aldrich (Saint Louis, MI/USA). All reagents used were of analytical grade or of the highest grade available.

Animals
Male Wistar Han rats, weighing in average 240 ± 35 g, were born at the Institute of Biomedical Sciences Abel Salazar - University of Porto (ICBAS-UP) animal facilities. Animals were kept under light/dark cycles of 12/12 h, at 22 ± 2 °C room temperature and 50-60 % humidity and had access to water and pellet food ad libitum. Handling and care of animals were conducted according to the European Union guidelines for animal research (2010/63/EU) and the current Portuguese Law (Decreto-Lei no. 113/2013, de 7 de Agosto). Moreover, animal experiments were licensed by the Organism responsible for the welfare of animals (ORBEA, ICBAS-UP; protocol no. 250/2018). All procedures were carried out considering the compliance of 3 R’s (replacement, reduction, refinement), providing appropriate animal care, minimizing their suffering and stress.
**Experimental protocol**

Before the experiment, animals were subjected to a short adaptation period to the metabolic cages, in order to reduce stress. Prior to TX5 or vehicle administration, animals were maintained in groups allowing social interactions. Two experiments were carried out, by using two distinct doses of TX5 hydrochloride (30 and 10 mg/kg, b.w.), administered by gavage. In the first experiment, a preliminary assessment of safety was performed by using four animals, two as controls and two treated with the highest dose of TX5 hydrochloride (30 mg/kg; TX5-30 group). In the second experiment, a lower dose of TX5 hydrochloride (10 mg/kg; TX5-10 group) was administered to perform the complete biochemical and histological evaluation, by using 14 animals (n = 7 controls; n = 7 TX5-treated). In both experiments, animals were fasted for 4 hours prior to gavage administration, while maintaining free access to water supplemented with 1 % sugar. Each animal was subjected to a brief inhalatory anesthesia with isoflurane to reduce the discomfort associated to the administration of the compound (or vehicle) by gavage. Immediately after the administration and for the next 24 hours, animals were individually housed in metabolic cages for whole urine collection. All animals were fasted for the last 12 hours before sacrifice, but water supplemented with 1 % sugar was given *ad libitum*. TX5 hydrochloride was prepared at the day of use in a concentration of 2 mg/mL in ultrapure water. A volume of 1 mL was administered per 200 g b.w. Control animals received ultrapure water using equivalent administration volumes of TX5-treated animals.

**Blood and urine collection and processing for hematological and biochemical analysis**

Twenty-four hours after TX5/vehicle administration, rats were deeply anesthetized with a mixture of xylazine and ketamine [10 and 90 mg/kg b.w., intraperitoneally (i.p.), respectively]. Animals were placed in the *decubito supino* position and the abdomen was opened, exposing the caudal cava vein, from which blood was collected and placed into heparin-, citrate- and EDTA-containing tubes. The blood collected into heparinized and citrate-containing tubes was centrifuged (1670 x g, 15 min at room temperature) and the obtained plasma was stored at -80 °C for further biochemical and coagulation analysis, respectively. Whole blood samples (collected using EDTA as anticoagulant) were used for hematological evaluations, namely erythrocyte count, hemoglobin (Hb) concentration, hematocrit, hematological indexes – mean cell volume (MCV), mean cell hemoglobin (MCH), mean cell hemoglobin concentration (MCHC), red cell distribution width (RDW), platelet (PLT) count, plateletcrit (PCT), platelet distribution width (PDW), mean platelet volume (MPV), total and differential white blood cell (WBC) count, using an automated blood cell counter (Sysmex K1000, Hamburg, Germany). Blood smears were stained according to Wright (International Committee for Standardization in Haematology, 1984) and blood cell morphology was observed. For the coagulation study, the prothrombin time (PT) and the activated partial thromboplastin time (APTT) were evaluated by using the clotting assay (Coagulation analyzer Coator M4, Teco Medical Instruments GmbH, Neufahrn, Germany; APTT-XL and TEClot PT-S, Teco Medical Instruments GmbH, Neufahrn, Germany).

The urine of each animal was collected 24 hours after TX5 or vehicle administration (metabolic cage) and centrifuged (3220 x g, 15 min at 4 °C). The resulting supernatants were separated and measured to assess the individual urinary flows (mL/day), and frozen at -80 °C for further analysis.

Plasma and urine samples were used to evaluate several clinical chemistry parameters on an AutoAnalyzer (PRESTIGE® 24i, PZ Cormay S.A.), using the respective kits and following the manufacturer’s instructions.

**Tissue collection and processing for histological and biochemical analysis**

Immediately after exsanguination, the liver, kidneys, heart, spleen, lungs, intestine
and brain were removed, washed in refrigerated saline solution (0.9 % NaCl), gently dried with filter paper and weighted to assess the relative organ weight (ROW, calculated as a percentage of the total body weight at the sacrifice day). Organs were then processed for histological and biochemical analysis.

**Histological analysis**

After animal sacrifice, pieces of the heart, small intestine, liver, kidneys, lungs, spleen and brain were randomly selected and immediately fixed in commercial 4 % buffered formalin for histopathological evaluation. After a fixation period of 24 hours, tissues were dehydrated through a series of graded ethanol solutions (70.0 – 99.8 %), cleared in xylene and impregnated and embedded in paraffin. Each organ was sectioned (Microtome – Leica RM 2255, Germany) into thin sections (4 µm thick). In order to improve section adhesion, the sampled sections were mounted in silane-coated microscope slides [Nuova Aparta, Canelli (AT), Italy]. The sections were then stained with H&E and PAS/Alcian Blue. For the histopathological analysis, the slides of all treatments were examined blinded and photographed under light microscope (BX50, Olympus, Japan) equipped with a digital camera (DP21, Olympus, Japan).

**Biochemical analysis**

The remaining tissue samples were homogenized in ice-cold 25 mM phosphate-buffered solution [1:4 (m/v), Ultra-Turrax® Homogenizer], pH 7.4. The homogenates were kept on ice, then centrifuged at 3000 x g for 10 min, at 4 °C. An aliquot of the resulting supernatants was separated for total protein quantification, and stored at -20 °C. Another aliquot of the resulting supernatants was precipitated with an equal volume of 10 % HClO₄ (5 % final acid concentration) and again centrifuged (16 000 x g, 10 min at 4 °C). Aliquots of the acidic supernatants were then separated and frozen at -80 °C for ATP quantification, and at -20 °C for total glutathione (tGSH) and oxidized glutathione (GSSG) quantification.

**Determination of tissue ATP levels**

The ATP levels of tissue homogenates were determined by bioluminescence, which is based on the generation of light using the luciferin-luciferase system (Costa et al., 2007; Rossato et al., 2014a). The method uses the enzyme luciferase that catalyzes the oxidation reaction of the luciferin reagent, consuming ATP. This reaction gives rise to light, being the amount of ATP present in the sample linearly proportional to the amount of light emitted. Briefly, 150 µL of the acidic supernatant referred in the section “Biochemical analysis” was neutralized with 150 µL of 0.76 M KHCO₃ and centrifuged (16 000 x g, 1 min at 4 °C). Bioluminescence was immediately read in a microplate reader Biotech Synergy HT (Winooski, VT/USA) after the reaction of 100 µL of neutralized supernatant with an equal volume of luciferin/luciferase solution (prepared in luciferin/luciferase buffer: 50 mM glycine, 10 mM MgSO₄, 1 mM Tris-HCl, 0.55 mM EDTA, 0.1 % BSA; pH 7.6). ATP standards were prepared in 5 % HClO₄ and treated like the samples. ATP intracellular levels were expressed in nmol of ATP per mg of protein.

**Determination of tissue total glutathione (tGSH) and oxidized glutathione (GSSG)**

The tGSH and GSSG levels of tissue homogenates were determined by the DTNB-GSSG reductase recycling assay (Costa et al., 2007; Teixeira-Gomes et al., 2016). The method involves oxidation of GSH by the sulfhydryl reagent DTNB to form the yellow derivative 5’-thio-2-nitrobenzoic acid (TNB), measurable at 415 nm. This formation is proportional to the concentration of GSH in the sample. The GSSG is recycled to GSH by GR, in the presence of NADPH. For the quantification of GSSG, 2-vinylpyridine was used to block GSH. The levels of GSH were determined considering the following formula: GSH = tGSH – 2 × GSSG. Briefly, for tGSH quantification, 200 µL of the acidic supernatant referred in the section “Biochemical analysis” was neutralized with 200 µL of 0.76 M KHCO₃ and centrifuged (16 000 x g, 2 min at 4 °C). For GSSG quantification, 10 µL of 2-
vinylpyridine was added to 200 μL of acidic supernatant, and the samples were shaken during 1 hour on ice prior to the neutralization step with 0.76 M KHCO₃. In 96-well plates, 100 μL of neutralized supernatant of sample, standard or blank were added in triplicate and mixed with 65 μL of fresh reagent solution containing 1.3 mM DTNB and 0.24 mM NADPH. Plates were incubated at 30 °C for 15 min in a plate reader (PowerWaveX; BioTek Instruments, Winooski, VT/USA) prior to the addition of 40 μL GR solution (10 U/mL). The final product of this reaction is a colored substance, and its formation was monitored for 3 min, at 415 nm, and compared with a standard curve (Pontes et al., 2008). GSH and GSSG standard solutions were prepared in 5 % HClO₄ and treated like the samples. Levels of tGSH, GSSG and GSH were normalized to the protein content (results are presented in nmol tGSH per mg of protein or nmol GSSG per mg of protein or nmol GSH per mg of protein).

**Determination of total protein tissue levels**

Protein quantification was carried out according to the method previously described by Lowry et al. (1951). An aliquot of the tissue homogenate supernatant referred in the section “Biochemical analysis” was used to assess the total tissue protein levels by spectrophotometry, using a microplate reader (wavelength = 750 nm). BSA standard curves were prepared in 0.5 M NaOH.

### Statistical analysis

Statistical analysis was performed with the GraphPad Prism software program version 6 (San Diego, CA/USA) and the results presented as means ± standard error of the mean (SEM). Outliers were identified using the ROUT test. The Shapiro–Wilk normality test was conducted before group comparison. Statistical comparison between control and TX5-exposed groups was estimated using the Unpaired Student t-test when the distribution was normal and the Mann-Whitney test when the distribution was not normal. A p value lower than 0.05 was considered to denote statistically significant differences.

### RESULTS

**Organ weights were not changed by TX5**

The individual weight of each organ (heart, liver, brain, kidneys, small intestine, spleen, lungs) was registered and the ratio organ weight/body weight (ROW) was calculated. Statistical analysis was only done for the TX5-10 group. No significant differences were observed between TX5-exposed and control animals for all collected organs (Table 1). Additionally, no differences were observed in the pattern of water intake and in the individual body weights between t = 0 h and t = 24 h (data not shown).

#### Table 1: Relative organ weight (ROW) of control and TX5-exposed animals

| Organ   | Control | TX5-30    | Control | TX5-10    |
|---------|---------|-----------|---------|-----------|
| Heart   | 0.34 ± 0.04 | 0.35 ± 0.01 | 0.38 ± 0.03 | 0.38 ± 0.03 |
| Liver   | 5.13 ± 0.35 | 5.45 ± 0.23 | 3.91 ± 0.17 | 3.85 ± 0.27 |
| Brain   | 0.67 ± 0.03 | 0.74 ± 0.00 | 0.82 ± 0.07 | 0.79 ± 0.05 |
| Kidneys | 0.86 ± 0.00 | 0.91 ± 0.01 | 0.95 ± 0.03 | 0.91 ± 0.04 |
| Intestine | 0.70 ± 0.32 | 0.66 ± 0.00 | 0.74 ± 0.12 | 0.60 ± 0.05 |
| Spleen  | 0.30 ± 0.02 | 0.29 ± 0.00 | 0.33 ± 0.04 | 0.31 ± 0.04 |
| Lungs   | 0.50 ± 0.02 | 0.52 ± 0.03 | 0.63 ± 0.04 | 0.55 ± 0.02 |

Relative organ weight (ROW) was calculated as percentage of the absolute body weight at sacrifice day. Results are presented as means ± standard error of the mean (SEM), and were obtained from two to seven animals in each group. Statistical comparisons were made using the Unpaired Student t-test. TX5-30 – thioxanthone 5, 30 mg/kg; TX5-10 – thioxanthone 5, 10 mg/kg.
**TX5 administration induced extensive hepatic necrosis at 30 mg/kg, but this effect was not observed at 10 mg/kg**

The morphology of the liver was very similar in animals from all groups. It was possible to observe the classic lobules defined as polygonal structures with several portal tracts at the periphery and a central vein in the center (Figure 1A). Hepatic cords or plates are composed of columns of hepatocytes extending from the portal region to the central vein. The spaces between the plates, seen as pale white regions, contain the liver sinusoids or “capillaries” of the liver. Due to the smaller size and decreased amount of connective tissue, portal regions may frequently be overlooked in histologic sections, being composed by four elements: arterioles, venules, bile ducts and lymphatics (Figure 1B). The main difference between the liver of control and TX5-10-exposed animals is the presence of a higher number of megakaryocytic cells in the animals exposed to TX5, denoting a reactive megakaryocytopoiesis (Figure 1C-F).

Regarding TX5-30 rats, extensive necrosis was observed (Figure 2). Intrahepatic glycogen and/or other glycoproteins were almost wholly concentrated in liver sections of TX5-exposed rats, mainly near the necrotic areas (Figure 2). These areas presented swelled cells, with clumping of nuclear chromatin and breaks in the plasma membrane. In small areas, the complete release of cellular components into the extracellular environment caused an inflammatory response. When both hepatocellular necrosis and destruction of the endothelial cells occurred, a central lobular hemorrhage into the zone of necrotic hepatocytes was observed.

**Figure 1:** Light microscopy photomicrographs of H&E stained sections of different liver regions from control (A and B) and TX5-10-treated (C–F) rats. CV, central vein; EN, endothelial cell; BD, bile duct; PR, portal region (dashed line); MEP, megakaryocytic precursors. CTR – Control group; TX5-10 – thioxanthone 5, 10 mg/kg group
**TX5 induced splenic parenchyma hyperemia at 30 mg/kg, but this effect was not observed at 10 mg/kg**

The substance of the spleen is divided into white and red pulp. White pulp consists of a cylindrical mass of lymphocytes arranged around a central artery that constitutes the periarterial lymphatic sheath (PALS). Splenic nodules occur along the length of the PALS. When observed in cross section through part of the sheath that contains a nodule, the central artery appears eccentrically located with respect to the lymphatic mass. Red pulp consists of splenic sinuses surrounded by splenic cords (cords of Billroth). The splenic red pulp is a normal site of low levels of hematopoiesis and a major site of reactive hematopoiesis (*i.e.*, myeloid, erythroid, and megakaryocytic hyperplasia). As in the liver, the main difference observed between control and TX5-10-exposed animals was a prominent megakaryocytic hyperplasia observed in the red pulp of the treated group (Figure 3C and D).

The spleen tissue from TX5-30 group exhibited marked histological changes characterized by splenic parenchyma with hyperemia of red pulp (Figure 3E and F). Additionally, small hemorrhagic areas were observed in some sections. In these animals, the volume of both white and red pulp increased, being the increase in the splenic red pulp more pronounced than that of the white pulp. Additionally, it was observed a significant increase of the marginal zone of the follicles (Figure 3E and F).

**TX5 did not cause any change in the heart at both doses**

Photomicrographs of H&E stained sections of myocardial tissue revealed that myocardial cytoplasm and nuclei were clear and well distributed. In all groups, cardiomyocytes with eosinophilic cytoplasm occupy the largest myocardium. In Figure 4, most muscular cells are oriented longitudinally, and the faint cross-striations are evident. Cardiomyocyte nuclei are large, with an ellipsoid shape, and contain granular chromatin with one or two nucleoli. Between cardiomyocytes it is observed loose connective tissue containing fibroblasts and capillaries lined by endothelial cells. Erythrocytes are present within capillar-
ies. No visible changes in the total of glycoproteins were observed in the animals of both groups. There was a very slight, non-relevant, hyperemia in the myocardium of the TX5-30 animals (Figure 4C). No visible changes in the total of glycoproteins occurred in the animals of all groups (Figure 4D herein for TX5-10 group).

Figure 3: Light microscopy photomicrographs of H&E stained sections of the spleen of control (A and B), TX5-10-exposed (C and D) and TX5-30-exposed (E and F) rats. CA, central artery; EH, erythroid hyperplasia; MEP, megakaryocytic precursors; MZ, marginal zone; PALS, periarterial lymphatic sheath; RP, red pulp; WP, white pulp. CTR – Control group; TX5-10 – thioxanthone 5, 10 mg/kg group; TX5-30 – thioxanthone 5, 30 mg/kg group.
**TX5 did not induce lung alterations**

No morphological alterations were found in the lungs of control and TX5-exposed rats, at both doses. Figure 5 is composed by photomicrographs of an intrapulmonary bronchi-ole, lined with columnar to cuboidal epithelium with some ciliated cells. The very thin lamina propria and submucosa separate epithelial cells from the muscular layer. The alveolar ducts have a wall formed by alveoli and sparse bundles of smooth muscle. The alveolar sacs have a wall formed completely by alveolar septa. Alveoli emanating from neighboring alveolar ducts and respiratory sacs are connected through pores in the alveolar septa.

**TX5 caused minor morphological alterations in the small intestine at 30 mg/kg**

In the small intestine of all animals, the villous epithelium is contiguous with the crypt epithelium, which is composed of surface absorptive cells (enterocytes), goblet cells, stem cells, Paneth cells and enteroendocrine cells (Figure 6). Enterocytes are tall columnar cells with an apical (luminal) surface covered with closely packed microvilli (brush border). Goblet cells are responsible for producing mucin. Stem cells divide rapidly to replenish the epithelium. The exocrine serous Paneth cells have abundant brightly eosinophilic cytoplasmic granules within their cytoplasm. Enteroendocrine cells exist near the basement membrane. Intraepithelial lymphocytes are also common. Plasma cells, macrophages, eosinophils and mast cells are also present in the lamina propria of small intestine. The muscularis externa consists of two concentric and relatively thick layers of smooth muscle. The cells in the inner layer form a tight spiral, described as a circularly oriented layer; those in the outer layer form a...
loose spiral, described as a longitudinally oriented layer. Within the connective tissue located between the two-muscle layer lies the myenteric plexus (also called Auerbach’s plexus), containing nerve cell bodies (ganglion cells), as well as blood vessels and lymphatic vessels (Figure 6). All these features are similarly observed in control and TX5-exposed animals. However, rats exposed to TX5, at both doses, apparently had an inflamed small intestine with the presence of a higher number of lymphocytes, eosinophils and mast cells, being in higher number in animals exposed to the higher dose (30 mg/kg) (Figure 6E and F).

Rats exposed to TX5 apparently had an increase in Paneth cells number, located at the base of crypts of Lieberkühn. The Paneth cells of rats administered with TX5 at higher dose (30 mg/kg) also had more and bigger cytoplasmic granules that were PAS positive (Figure 7). Additional morphologic relevant alterations were not observed in the small intestine.
Figure 6: Light microscopy photomicrographs of H&E stained sections of the rat small intestine from control (A and B), TX5-10-treated (C and D) and TX5-30-treated (E and F) rats. AP, Auerbach’s plexus; C, circular (inner) layer of muscularis externa; E, enteroendocrine; EC, enterocytes; Eo, eosinophils; GC, goblet cells; IGI, intestinal glands (crypts); L, longitudinal (outer) layer of muscularis externa; LP, lamina propria; LY, lymphocytes; M, mastocytes; PC, Paneth cells; V, villi. CTR – Control group; TX5-10 – thioxanthone 5, 10 mg/kg group; TX5-30 – thioxanthone 5, 30 mg/kg group
TX5 caused a slight hyperemia and tubular edema in rat kidneys at 30 mg/kg

The kidney cortex consists of renal corpuscles along with the convoluted tubules and straight tubules of the nephron, the collecting tubules, collecting ducts, and an extensive vascular supply. The kidney medulla is characterized by straight tubules, collecting ducts and a special capillary network, the vasa recta. In the kidneys, normal glomerular and tubular histology was registered in animals of both control and TX5-10 group (Figure 8).

Figure 7: Photomicrographs of H&E (A, B, D, E) and PAS/Alcian Blue (C and F) stained sections of small intestine of TXS-30 group (thioxanthone 5, 30 mg/kg). Thin arrows – Mastocytes; Thick arrows – Eosinophils; Dashed arrow – Paneth cells

Figure 8: Light microscopy photomicrographs of H&E stained sections of the kidneys from control (A and C) and TXS-10-treated (B and D) rats. CT, collecting tubule; DT, distal tubule; GL, glomerulus; MD, macula densa; PT, proximal tubule; VP, vascular pole of renal corpuscle; UP, urinary pole of renal corpuscle. CTR – Control group; TXS-10 – thioxanthone 5, 10 mg/kg group
On the contrary, the kidneys of TX5-30 rats presented a slight hyperemia (Figure 9A and B) and tubular edema (Figure 9B).

**TX5 did not cause brain histopathological changes**

Microscopic assessment is a well-validated approach for evaluating nervous system structural abnormalities in rodents, providing an excellent correlation with gross pathology. In this study, the nervous system cytoarchitecture was normal in animals of all groups. All animal’s hippocampus evidenced pyramidal neurons which were densely packed and of small size. Gray matter has cell bodies neurons associated with neuropil that is a meshwork of axonal, dendritic and glial processes (data not shown). No differences were observed in the cerebellum of control and TX5-exposed rats. The peripheral gray matter is uniformly organized in three layers, which are (from outside to inside) the molecular layer, Purkinje cell layer and the granular layer. The molecular layer is a broad expanse of densely packed neuronal processes with few neuronal bodies. The Purkinje cell layer is a monolayer of large, torpedo-shaped cells with prominent apical processes extending into the molecular layer. The granular layer is packed with small, dark, round granule cells and Golgi cells (Figure 10A and C). The choroid plexus, modified ependymal cells that cover the capillary loops and are responsible for the production of the cerebrospinal fluid (CSF), had normal appearance and contained the normal amount of glycoproteins, as revealed by PAS/Alcian Blue histochemistry (Figure 10D).

**No changes in both plasma and hematological parameters, but a higher tendency to blood coagulation after TX5 administration**

Given the evident histological alterations observed in the rats administered with TX5 30 mg/kg in the pilot assay, we continued this study by electing the lower dose tested (10 mg/kg) for which, as mentioned before, no important histopathological changes were observed in any evaluated organs, with the exception of a moderate megacaryocytic hyperplasia in both the liver and the spleen. TX5 (10 mg/kg) did not induce any alteration in either the plasma biochemical or the hematological parameters evaluated (Table 2). Several parameters were measured as biomarkers of toxic effect. Particularly, the plasma levels of AST, ALT, CK, CK-MB, creatinine and urea were measured 24 hours after exposure to TX5 (10 mg/kg) as biomarkers of liver, heart, muscle or kidneys integrity. There were no significant differences in any of these parameters between control and TX5-exposed...
rats. Moreover, the AST/ALT ratio was also calculated and no differences were found (data not shown). Very importantly, TX5 was able to cause a significant decrease in APTT when compared to control animals (14.4 ± 0.4 seconds versus 18.3 ± 0.5 seconds, respectively), without alterations in PT, as shown in Table 2.

Additionally, in the urine, as can be observed in Table 3, no differences were observed in the biochemical parameters evaluated between control and TX5-exposed rats, with the exception of creatinine and sodium, both of which suffered a TX5-induced increase relatively to control animals (35.96 ± 3.93 versus 21.97 ± 3.43 mg/kg/day and 1.95 ± 0.31 versus 1.13 ± 0.19 nmol/kg/day, respectively).
Table 2: Plasma and hematological parameters of control and TX5-exposed (10 mg/kg) animals

| Parameter                        | Control          | TX5              |
|----------------------------------|------------------|------------------|
| Total proteins (g/dL)            | 5.09 ± 0.31      | 5.36 ± 0.24      |
| Albumin (g/dL)                   | 3.94 ± 0.28      | 3.75 ± 0.12      |
| AST (U/L)                        | 113.28 ± 12.88   | 126.79 ± 4.07    |
| ALT (U/L)                        | 24.74 ± 6.34     | 21.04 ± 2.06     |
| Urea (mg/dL)                     | 47.08 ± 8.16     | 47.37 ± 9.15     |
| Creatinine (mg/dL)               | 1.05 ± 0.47      | 0.42 ± 0.11      |
| Uric acid (mg/dL)                | 1.10 ± 0.21      | 2.11 ± 0.66      |
| Glucose (mg/dL)                  | 195.42 ± 24.56   | 184.01 ± 23.29   |
| Lactate (mg/dL)                  | 64.49 ± 11.06    | 77.46 ± 9.93     |
| Cholesterol (mg/dL)              | 63.76 ± 5.15     | 58.24 ± 4.78     |
| Triglycerides (mg/dL)            | 73.68 ± 15.32    | 69.47 ± 11.03    |
| Iron (µg/dL)                     | 264.44 ± 38.13   | 274.53 ± 39.01   |
| LDH (U/L)                        | 1134.16 ± 382.36 | 1159.87 ± 335.32 |
| CK (U/L)                         | 728.20 ± 71.52   | 967.91 ± 188.11  |
| CK-MB (U/L)                      | 35.35 ± 7.34     | 32.66 ± 6.15     |
| Pseudocholinesterase (U/L)       | 723.74 ± 187.33  | 864.85 ± 121.77  |
| Amylase (U/L)                    | 644.12 ± 47.12   | 634.56 ± 39.08   |
| Hemoglobin (g/dL)                | 15.0 ± 0.4       | 15.3 ± 0.5       |
| Hematocrit (%)                   | 45.2 ± 2.0       | 44.6 ± 1.8       |
| RBC (x10^{12}/L)                 | 7.77 ± 0.28      | 7.79 ± 0.27      |
| MCV (fL)                         | 58.0 ± 0.9       | 57.0 ± 0.9       |
| MCH (pg)                         | 19.4 ± 0.3       | 19.8 ± 0.3       |
| MCHC (g/dL)                      | 33.3 ± 0.6       | 34.4 ± 0.5       |
| RDW (%)                          | 12.7 ± 0.3       | 12.6 ± 0.4       |
| Platelet (x10^9/L)               | 667 ± 20.3       | 538 ± 118        |
| PCT (%)                          | 0.49 ± 0.03      | 0.40 ± 0.09      |
| PDW (%)                          | 9.0 ± 0.5        | 7.9 ± 1.3        |
| MPV (fL)                         | 7.3 ± 0.3        | 7.3 ± 0.3        |
| WBC (x10^9/L)                    | 3.7 ± 0.9        | 3.5 ± 0.3        |
| Granulocytes (x10^9/L)           | 0.5 ± 0.2        | 0.5 ± 0.1        |
| Lymphocytes (x10^9/L)            | 2.8 ± 0.7        | 2.7 ± 0.3        |
| Monocytes (x10^9/L)              | 0.4 ± 0.1        | 0.4 ± 0.0        |
| APTT (seconds)\(^*\)             | 18.3 ± 0.5       | 14.4 ± 0.4\(^*\)* |
| PT (seconds)\(^*\)              | 23.18 ± 0.77     | 22.93 ± 0.68     |

Results are presented as means ± standard error of the mean (SEM) and were obtained from five to seven animals in each group. Statistical comparisons were made using the Unpaired Student t-test or the Mann-Whitney test (**\(p < 0.0001\) TX5 vs. control). APTT - activated partial thromboplastin time; PT - prothrombin time

\(^*\)\(n\) varies between three and four animals in each experimental group

\(^*\)\(n\) varies between two and four animals in each experimental group
Table 3: Urine biochemical parameters of control and TX5-exposed (10 mg/kg) animals

| Parameter      | Control               | TX5                  |
|----------------|-----------------------|----------------------|
| Total proteins (mg/kg/day) | 1710 ± 382            | 2082 ± 480.6         |
| Albumin (mg/kg/day)       | 18.29 ± 2.41          | 31.48 ± 6.33         |
| Urea (mg/kg/day)          | 284.2 ± 95.47         | 197.9 ± 34.94        |
| Creatinine (mg/kg/day)    | 21.97 ± 3.43          | 35.96 ± 3.93*        |
| Uric acid (mg/kg/day)     | 5.13 ± 0.70           | 6.43 ± 0.84          |
| Glucose (mg/kg/day)       | 15.69 ± 3.40          | 16.54 ± 2.22         |
| Phophorus (mg/kg/day)     | 16.00 ± 3.34          | 13.27 ± 2.44         |
| Calcium (mg/kg/day)       | 5.78 ± 1.25           | 7.73 ± 1.69          |
| Iron (µg/kg/day)          | 83.31 ± 23.08         | 118.0 ± 28.38        |
| Magnesium (mg/kg/day)     | 4.19 ± 0.91           | 4.13 ± 0.54          |
| Chloride (nmol/kg/day)    | 5.44 ± 0.75           | 7.12 ± 1.15          |
| Sodium (nmol/kg/day)      | 1.13 ± 0.19           | 1.95 ± 0.31*         |

Results are presented as means ± standard error of the mean (SEM) and were obtained from six to seven animals in each group. Statistical comparisons were made using the Unpaired Student t-test (*p <0.05 TX5 vs. control).

**TX5 increased ATP content in the small intestine**

As can be observed in Figure 11 and Table 4, TX5 significantly increased the ATP levels in the small intestine (0.34 ± 0.06 nmol/mg of protein) relatively to the control animals (0.19 ± 0.02 nmol/mg of protein), 24 hours after administration of the compound. No other changes in ATP content were evoked by TX5 in any of the other organs evaluated.

![Figure 11: ATP levels in the heart (A), liver (B), brain (C), kidneys (D), intestine (E), spleen (F) and lungs (G) after TX5 (10 mg/kg) administration. Results, in nmol per mg of protein (nmol/mg), are presented as means ± standard error of the mean (SEM) and were obtained from six to seven animals in each group. Statistical comparisons were made using the Unpaired Student t-test (*p <0.05 TX5 vs. control).](image-url)
Table 4: Effect of TX5 (10 mg/kg) administration in oxidative stress-related parameters and ATP levels in the seven evaluated organs

| Parameter | Control | TX5 |
|-----------|---------|-----|
| Heart     |         |     |
| tGSH (nmol/mg protein) | 15.46 ± 3.70 | 22.27 ± 4.35 |
| GSH/GSSG ratio | 20.56 ± 5.15 | 21.43 ± 1.71 |
| GSSG (nmol/mg protein) | 1.06 ± 0.26 | 1.02 ± 0.24 |
| GSH (nmol/mg protein) | 16.30 ± 3.35 | 20.23 ± 3.94 |
| ATP (nmol/mg protein) | 0.41 ± 0.05 | 0.37 ± 0.03 |
| Liver     |         |     |
| tGSH (nmol/mg protein) | 51.13 ± 5.19 | 48.43 ± 9.13 |
| GSH/GSSG ratio | 0.52 ± 0.09 | 0.21 ± 0.17 |
| GSSG (nmol/mg protein) | 21.36 ± 1.97 | 25.03 ± 4.18 |
| GSH (nmol/mg protein) | 10.88 ± 2.56 | 5.88 ± 6.67 |
| ATP (nmol/mg protein) | 0.13 ± 0.03 | 0.19 ± 0.05 |
| Brain     |         |     |
| tGSH (nmol/mg protein) | 14.32 ± 2.44 | 10.66 ± 2.64 |
| GSH/GSSG ratio | 13.33 ± 2.20 | 11.34 ± 2.78 |
| GSSG (nmol/mg protein) | 1.00 ± 0.24 | 0.66 ± 0.07 |
| GSH (nmol/mg protein) | 11.98 ± 2.53 | 7.64 ± 2.33 |
| ATP (nmol/mg protein) | 0.40 ± 0.05 | 0.37 ± 0.06 |
| Lungs     |         |     |
| tGSH (nmol/mg protein) | 8.154 ± 1.52 | 11.57 ± 2.42 |
| GSH/GSSG ratio | 5.38 ± 0.74 | 9.38 ± 1.46* |
| GSSG (nmol/mg protein) | 1.42 ± 0.26 | 1.08 ± 0.21 |
| GSH (nmol/mg protein) | 6.41 ± 1.16 | 9.41 ± 2.10 |
| ATP (nmol/mg protein) | 0.10 ± 0.01 | 0.13 ± 0.02 |
| Kidneys   |         |     |
| tGSH (nmol/mg protein) | 0.051 ± 0.005 | 0.062 ± 0.004 |
| ATP (nmol/mg protein) | 0.25 ± 0.02 | 0.23 ± 0.02 |
| Spleen    |         |     |
| tGSH (nmol/mg protein) | 18.53 ± 1.46 | 21.23 ± 2.95 |
| GSH/GSSG ratio | 2.23 ± 0.37 | 2.77 ± 0.81 |
| GSSG (nmol/mg protein) | 4.47 ± 0.35 | 4.69 ± 0.51 |
| GSH (nmol/mg protein) | 9.60 ± 1.32 | 11.84 ± 2.96 |
| ATP (nmol/mg protein) | 0.41 ± 0.03 | 0.48 ± 0.05 |
| Intestine |         |     |
| tGSH (nmol/mg protein) | 18.32 ± 3.57 | 11.70 ± 2.87 |
| GSH/GSSG ratio | 6.20 ± 0.68 | 4.64 ± 1.86 |
| GSSG (nmol/mg protein) | 1.70 ± 0.55 | 2.16 ± 0.37 |
| GSH (nmol/mg protein) | 13.65 ± 2.54 | 7.39 ± 2.54 |
| ATP (nmol/mg protein) | 0.19 ± 0.02 | 0.34 ± 0.06* |

Total glutathione (tGSH), the ratio of reduced (GSH) and oxidized (GSSG) glutathione levels, oxidized glutathione (GSSG), reduced glutathione (GSH) and adenosine triphosphate (ATP) levels, in the heart, liver, brain, lungs, kidneys, spleen and intestine of control and TX5-treated rats. Data of tGSH, GSSG, GSH and ATP levels in nmol per mg of protein (nmol/mg protein), and the GSH/GSSG ratio are presented as means ± standard error of the mean (SEM), and were obtained from four to seven animals in each group. Statistical comparisons were made using the t-test when the distribution was normal or the Mann Whitney test when the distribution was not normal (*p < 0.05 TX5 vs. control).

**DISCUSSION**

The history related to TXs is already long. The last twenty years were rich in disclosing new and challenging therapeutic applications for these compounds (Paiva et al., 2013). Among them, TX5, a novel aminated thioxanthonic compound, has being deserved our attention in recent years, since docking studies uncovered its potential as a P-gp modulating
agent (Palmeira et al., 2012). Moreover, according to our previous data, TX5 showed to be a P-gp inducer and activator in vitro, in Caco-2 cells (Silva et al., 2015a, b), as well as ex vivo, using the rat ileum as a model (data submitted for publication). Based on these findings, the present study aimed at performing a preliminary in vivo safety study. It consisted in a first experiment in which a few number of Wistar Han rats (n = 2 controls and n = 2 TX5-treated) were administered, by gavage, with TX5 30 mg/kg b.w. This dose was selected according to a previous in vivo pharmacokinetic study (submitted elsewhere). During the 24 hours of the protocol, both putative behavior changes and the pattern of water and food ingestion were monitored and no alterations were noted. No differences were registered in the ROW, but it is not feasible to take strong conclusions given the low number of animals used in this first approach. In order to evaluate the degree of tissue damage due to TX5 treatment, we monitored tissue sections using microscopy. The histopathological analysis performed in the several organs (heart, liver, spleen, kidneys, small intestine, lungs and brain) revealed toxicity, particularly evident in the liver and spleen. We observed extensive hepatic necrosis (Figure 2), as well as hyperemia of the splenic parenchyma (Figure 3E and F). Moreover, signs of red pulp hemorrhage were observed in some sections after TX5 administration. Although with a mild degree of expression, it was observed a slight hyperemia in the myocardium of the animals exposed to TX5 (30 mg/kg), as well as an inflamed small intestine revealed by the presence of a higher number of lymphocytes, eosinophils and mast cells. Besides, the kidneys of the animals exposed to this dose of TX5 presented tubular edema and a slight hyperemia. On the contrary, there were no deleterious histological effects in the brain and the lungs. Given the impact of the histopathological analysis in the safety assessment of compounds, we considered these effects to be relevant. Consequently, the study was proceeded by testing a lower dose of TX5.

Thus, in the second experiment, seven animals were administered with 10 mg/kg dose under the same protocol described for the highest dose tested. No differences were registered neither in the ROW nor in the water ingestion pattern. In histopathological terms, no relevant alterations were observed in any of the organs analyzed. Only a minor inflammation in the small intestine seemed to be present given the small number of inflammatory cells observed. Noteworthy, the necrotic effect in the liver observed with TX5 30 mg/kg was no longer observed with TX5 10 mg/kg. Additionally, at the lowest dose tested, the splenic toxic effects were not observed.

The bone marrow is the major hematopoietic organ and a primary lymphoid organ responsible for the production of red cells, leukocytes and platelets, in response to systemic needs (Travlos, 2006). However, it is known that extramedullary hematopoiesis occurs physiologically in the juvenile rat, presenting a tendency to decrease gradually with age and increasing in response to environmental stimuli (Figueiredo et al., 2016; Parker and Papenfuss, 2016). In the rat and the mice, extramedullary hematopoiesis has been recorded in the spleen, liver, lymphnode, kidney and adrenals (Raval et al., 2014). Hematopoiesis in juvenile rats occurs primarily in liver and spleen. Particularly, it is common in rodent red pulp, especially in fetal and neonatal animals. Any combination of erythroid, myeloid and megakaryocytic cells may be evident (Cesta, 2006; Parker and Papenfuss, 2016). The histopathological analysis revealed the presence of megakaryocytopoiesis in the liver and in the spleen red pulp of both control and TX5-treated rats. Nonetheless and very interestingly, our qualitative analysis showed an apparent more prominent megakaryocytopoiesis in the liver and spleen of the animals exposed to TX5 (10 mg/kg) when compared to control rats. As stated before, extramedullary hematopoiesis can be increased as a consequence of xenobiotic’s treatment (Domingues et al., 2011; Mahiout et al., 2017), an aspect that is in accordance with our findings. No signs of necrosis, lymphocytic infiltrate or
hemothage were found in TX5-administered animals (10 mg/kg), in any of the other organs analyzed.

By the exposed, comparing the two doses tested, the histopathological findings showed that the lowest dose was apparently safe. As such, hematological and biochemical analysis were then performed. Indeed, the qualitative histological analysis only gives an indication of the degree of toxicity and should be combined with biochemical data to ascertain the overall toxicity induced by the compound. Alternatively, whenever changes are slight, quantification should be carried out so that they can be used, by themselves, in the conclusion of the observed results.

The investigation of clinical pathology parameters (hematology, clinical chemistry and coagulation) is an important part of the preclinical evaluation of drug safety (Seibel et al., 2010). In the present study, none of the hematological and biochemical parameters determined in the plasma of the animals showed any change due to exposure to TX5 (10 mg/kg).

We have also evaluated the possible interference of TX5 on blood coagulation. Hemostasis is a cell-based process that is regulated in a tissue-specific manner by the differential expression of pro-coagulant and anticoagulant factors on endothelial cells from different sites throughout the vasculature (Fager and Hoffman, 2018). Regarding coagulation, PT, APTT and thrombin time (TT) are the most commonly used clotting time assays in mammals. In fact, APTT and PT are the recommended laboratory tests of hemostasis for non-clinical toxicity and safety studies (Weingand et al., 1992). PT, APTT and TT assess the function of the extrinsic, the intrinsic and the common pathways (Takahashi et al., 2011). APTT can be used to evaluate the intrinsic and common pathways of coagulation and may be prolonged due to anticoagulant therapy, clotting factor deficiencies, lupus anticoagulant or acquired inhibitors of specific clotting factors (Loizou et al., 2018; Winter et al., 2017). Furthermore, it is known that there are differences in the time required for coagulation between species (Tabata et al., 1995). Moreover, there are gender intra-species differences in the hemostatic parameters PT, APTT, TT and fibrinogen (Lemini et al., 2007). In the rat, blood coagulation is faster than that in humans. On the other hand, according to Seibel and colleagues (2010), the coagulation parameters might be susceptible to the sampling method used. Specifically, the authors compared PT and APTT from Sprague-Dawley blood samples collected terminally from the vena cava immediately before necropsy with samples taken from the sublingual vein also prior to necropsy. The results showed that APTT was significantly decreased in blood taken from the vena cava than that taken from the sublingual vein (Seibel et al., 2010). In the present study, the values obtained for APTT in control rats were in accordance to those reported by Seibel et al. for the same vascular territory (Seibel et al., 2010). Additionally, the APTT and PT values in the present study are in line with those presented by Lemini and colleagues, who studied the influence of species and gender in coagulation tests (Lemini et al., 2007). Interestingly, according to our results, TX5 seems to accelerate blood coagulation. This pro-coagulant effect is revealed by a significantly reduction in the APTT of the rats exposed to TX5, when compared to the controls. Since no alterations were observed in PT, we hypothesize that the hemostatic effect is due to a change in the coagulation factors belonging to the intrinsic pathway, namely in factors VIII, IX, XI and/or XII. This TX5-mediated decrease of APTT may have implications in hemostasis management. Particularly, TX5 could confer protection against bleeding, at the potential expense of increased thrombotic risk.

The kidney normally functions to maintain hemodynamic homeostasis and is a major site of damage caused by xenobiotic toxicity (Fisch et al., 2016). Acute kidney injury is a heterogeneous group of conditions characterized by a sudden decrease in glomerular filtration rate (GFR), manifested by an increase in serum creatinine concentration or oliguria,
and can be a consequence of drug toxicity (Levey and James, 2017). Several urine biochemical parameters were measured to assess whether TX5 was able to induce renal toxicity, under the experimental conditions. Differently to the plasma biochemical results obtained, TX5 was able to significantly increase urinary creatinine and sodium. Creatinine is the final product of creatine phosphate catabolism. It is excreted in the kidneys via glomerular filtration, being a measure of GFR and a biomarker of renal injury (Wyss and Kaddurah-Daouk, 2000). The increase in serum and urine creatinine was considered to represent an index of cisplatin-induced nephrotoxicity in Wistar rats, in such a way that the reversion of the toxic effect occurs through the normalization of these values (Khairnar et al., 2019). Therefore, the urinary creatinine result may indicate some change at the renal level without a concomitant increase in plasma creatinine. In our study, plasma and urine urea levels were not altered by TX5. Similarly to our results, Lima and co-authors have shown that treatment with TXA1 hydrochloride (50 mg/kg, by subcutaneous injection 3 times per week), a TX5-related thioxanthonic compound, did not induce any change in both serum creatinine and urea of nude xenografted mice, 22 days after first treatment (Lima et al., 2018). However, TX1 hydrochloride was able to cause an alteration in steroid biosynthesis and an abnormal cellular cholesterol localization, both in vitro and in vivo (Lima et al., 2018). The elevation in urinary creatinine observed in the present study would suggest the presence of histological alterations in the kidneys, which, however, were not observed. This is a very important conclusion in terms of a preliminary toxicity evaluation. In fact, a normal glomerular and tubular histology were seen in animals of both control and TX5-10 groups. Renal histopathological abnormalities were observed only at the highest dose (30 mg/kg) and were manifested by mild hyperemia and tubular edema. Additionally, TX5-10 rats presented a higher amount of sodium in urine when comparing to control animals. However, this effect was not accompanied by a concomitant increase in urinary volumes due to the osmotic effect of the electrolyte. We hypothesize that these results may indicate the ability of TX5 to alter sodium homeostasis, particularly by interfering with sodium reabsorption at tubular level. Nonetheless, the increase in sodium excretion might be a beneficial effect of the compound for certain pathological conditions. In fact, a similar effect was reported by other authors while studying antidiabetic agents and their impact in cardiovascular outcomes. In this regard, Lin and colleagues (2014) reported that empagliflozin (per os, with standard diet containing empagliflozin 0.03 %), an inhibitor of the renal sodium/glucose co-transporter 2 (SGLT2) located at the apical membrane of the renal tubular epithelial cells, was able to significantly increase renal sodium excretion in the db/db mice diabetic model, on day 1 of treatment (Lin et al., 2014). Although our results require further investigation, the possibility of TX5 being able to positively interfere with sodium homeostasis appears to be of great importance in the cardiovascular context.

We also tried to understand if TX5 could possibly cause toxicity by interfering with energetic metabolism and/or oxidative stress. Our study shows that TX5 did not cause significant alterations in the glutathione levels (tGSH, GSGS, GSH) of the several organs analyzed. Only an increase in the GSH/GSSG ratio was observed in the lungs of the rats exposed to TX5. This can be an indication of an interference of TX5 in the antioxidant defenses in this organ. The energetic metabolism was altered by TX5, with a significant increase in ATP levels, an effect observed exclusively in the small intestine of TX5-exposed animals (10 mg/kg). This effect might be related to an impairment in the bioenergetics in this organ induced by TX5. The lack of in vitro and in vivo data in the literature related to the interference of thioxanthonic compounds in bioenergetics and oxidative stress processes turns the discussion of our re-
sults more difficult. It is known that ATP bi-
availability is related to mitochondrial func-
tion (Burke, 2017). For example, one im-
portant mechanism of cytotoxicity relies on
the induction of the mitochondrial permeabil-
ity transition (MPT), which causes mitochon-
drial failure, leading to necrosis from ATP de-
pletion or caspase-dependent apoptosis if
ATP depletion does not occur fully (Jaeschke
et al., 2002). In this regard, several studies re-
port ATP depletion as a consequence of xeno-
biotic-induced mitochondrial disruption in
distinct tissues, such as the liver, heart and
brain (Barbosa et al., 2015; Rossato et al.,
2014a, b; Shi et al., 2018; Shiba et al., 2011).
In contrast, we found an increase in the intra-
cellular concentration of ATP in the intestine
of TX5-treated animals. Although, in the pre-
sent study, mitochondrial morphologic
changes were not observed in the intestine, we
cannot exclude the existence of functional mi-
tochondrial disturbances that could putatively
explain the changes in ATP intestinal content
found in TX5-exposed animals. This finding
requires further research. We hypothesize that
the increase in intestinal ATP might be related
with the mechanism of action of TX5, i.e., the
TX5-mediated P-gp activator effect observed
in the rat intestinal mucosa ex vivo (results
submitted elsewhere). In fact, P-gp is an en-
ergy-dependent efflux protein, so its exacer-
bated activity induced by TX5 requires a
greater supply of ATP and, consequently, the
increase in ATP content observed in this
study. Following this logic, there are studies
reporting a decrease in tissue ATP levels as-
associated with a reduction in the activity of
ATP-dependent efflux carrier proteins in rats
(Aleo et al., 2014; Slater and Delaney, 1970)
and humans (Chijiiwa et al., 2002). These ef-
effects, in turn, might be related to alterations in
enzymatic activity, such as ATP synthase or
ATPase. Indeed, ATP synthase is a central en-
zyme of the cellular energy metabolism and
could constitute a target in reprogramming
energetic metabolism (Bianchi et al., 2018).
Alternatively, the increase in ATP content ob-
served in the intestine of TX5-treated rats
could be due to an involvement in the inflam-
matory process observed, revealed by the
presence of a higher number of lymphocytes,
eosinophils and mast cells (Figure 6). Indeed,
other authors have demonstrated that ATP in-
fluences the response of intestinal epithelial
cells to TLR ligands and favors the matura-
tion of dendritic cells to become inflamma-
tory (Yao et al., 2012). Another explanation
might be the ability of TX5 to induce transient
changes in ATP intestine levels, with an in-
crease after a short period of exposure, fol-
lowed by a return to normal levels after a
longer exposure period. Accordingly, transi-
tent changes in ATP brain levels following
amphetamine exposure, namely MDMA,
were reported, although, in these cases, with a
decrease after a short contact and a long-term
returning to control values (Barbosa et al.,
2015; Teixeira-Gomes et al., 2016). As previ-
ously stated, the TX5-induced increase in in-
testinal ATP content found in the present
study deserves further investigation in order
to unveil the possible mechanisms underlying
this finding.

In summary, this study highlights the: 1)
presence of relevant histological hepatic and
splenic toxicity induced by TX5 (30 mg/kg);
2) absence of histological damage with TX5
(10 mg/kg); 3) APTT decrease in TX5 (10
mg/kg) animals; 4) creatinine and sodium in-
crease in the urine of TX5 (10 mg/kg) rats; 5)
increased ATP levels in the small intestine of
TX5 (10 mg/kg) group; 6) absence of relevant
oxidative stress deregulation in all studied or-
gans.

Taken together, our results show that
TX5, at a 10 mg/kg dose, does not induce sig-
nificant toxicity in the several biological ma-
trices studied but may possibly have a pro-co-
agulant effect. The renal and intestinal effects
observed require more research, although do
not constitute a source of relevant toxicity.

This study encourages further investiga-
tion of this molecule considering its activator
effect, already demonstrated by us, of the im-
portant P-gp efflux transporter at the rat intesti-
nal mucosa, ex vivo. This finding brings us
closer to the use of this compound, with an
adequate safety/efficacy relationship, as an antidote or therapeutic adjuvant in the pharmacological approach to intoxications caused by P-gp substrates.

**Funding**

This research was developed under the Project NORTE-01-0145-FEDER-000024, supported by Norte Portugal Regional Operational Programme (NORTE2020), under the PORTUGAL 2020 Partnership Agreement (DESgnBIOtecHealth—New Technologies for three Health Challenges of Modern Societies: Diabetes, Drug Abuse and Kidney Diseases) and Project No. POCI-01-0145-FEDER-028736, co-financed by COMPETE 2020, Portugal 2020 and the European Union through the ERDF, and by FCT through national funds. This work was also supported by UID/MULTI/04378/2019 with funding from FCT/MCTES, through national funds.

**REFERENCES**

Aleo MD, Luo Y, Swiss R, Bonin PD, Potter DM, Will Y. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology. 2014;60:1015-22.

Barbosa DJ, Capela JP, Feio-Azevedo R, Teixeira-Gomes A, Bastos Mde L, Carvalho F. Mitochondria: key players in the neurotoxic effects of amphetamines. Arch Toxicol. 2015;89:1695-725.

Bianchi G, Ravers S, Traverso C, Amaro A, Piaggio F, Emionite L, et al. Curcumin induces a fatal energetic impairment in tumor cells in vitro and in vivo by inhibiting ATP-synthase activity. Carcinogenesis. 2018;39:1141-50.

Burke PJ. Mitochondria, bioenergetics and apoptosis in cancer. Trends Cancer. 2017;3:857-70.

Cesta MF. Normal structure, function, and histology of the spleen. Toxicol Pathol. 2006;34:455-65.

Chijiwa K, Mizuta A, Ueda J, Takamatsu Y, Nakamura K, Watanabe M, et al. Relation of biliary bile acid output to hepatic adenosine triphosphate level and biliary indocyanine green excretion in humans. World J Surg. 2002;26:457-61.

Costa VM, Silva R, Ferreira LM, Branco PS, Carvalho F, Bastos ML, et al. Oxidation process of adrenaline in freshly isolated rat cardiomyocytes: formation of adrenochrome, quinoproteins, and GSH adduct. Chem Res Toxicol. 2007;20:1183-91.

Couture L, Nash JA, Turgeon J. The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart. Pharmacol Rev. 2006;58:244-58.

DeGorter MK, Xia CQ, Yang JJ, Kim RB. Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol. 2012;52:249-73.

Dinis-Oliveira RJ, Remiao F, Duarte JA, Ferreira R, Sanchez Navarro A, Bastos ML, et al. P-glycoprotein induction: an antidotal pathway for paraquat-induced lung toxicity. Free Radic Biol Med. 2006;41:1213-24.

Domingues A, Barbisan LF, Martins PR, Spinardi-Barbisan AL. Diuron exposure induces systemic and organ-specific toxicity following acute and sub-chronic exposure in male Wistar rats. Environ Toxicol Pharmacol. 2011;31:387-96.

Fager AM, Hoffman M. Biology of coagulation and coagulopathy in neurologic surgery. Neurosurg Clin N Am. 2018;29:475-83.

Figueiredo JF, Mattix ME, Papenfuss TL. Hematopoietic system. In: Parker G, Picut C (eds): Atlas of histology of the juvenile rat (pp 349-71). Cambridge, MA: Academic Press, 2016.

Fisch S, Liao R, Hsiao LL, Lu T. Early detection of drug-induced renal hemodynamic dysfunction using sonographic technology in rats. J Vis Exp. 2016;109:52409.

Gameiro M, Silva R, Rocha-Pereira C, Carmo H, Carvalho F, Bastos ML, et al. Cellular models and in vitro assays for the screening of modulators of P-gp, MRP1 and BCRP. Molecules. 2017;22(4):1-48.

International Committee for Standardization in Haematology. ICSH reference method for staining of blood and bone marrow films by azure B and eosin Y (Romanowsky stain). Br J Haematol. 1984;57:707-10.

Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol Sci. 2002;65:166-76.

Khairnar SI, Mahajan UB, Patil KR, Patel HM, Shinde SD, Goyal SN, et al. Disulfiram and its copper chelate attenuate cisplatin-induced acute nephrotoxicity in rats via reduction of oxidative stress and inflammation. Biol Trace Elem Res. 2019; epub ahead of print.
Lemini C, Jaimez R, Franco Y. Gender and inter-species influence on coagulation tests of rats and mice. Thromb Res. 2007;120:415-9.

Levey AS, James MT. Acute kidney injury. Ann Intern Med. 2017;167:ITC66-80.

Lima RT, Sousa D, Gomes AS, Mendes N, Matthiesen R, Pedro M, et al. The antitumor activity of a lead thioxanthone is associated with alterations in cholesterol localization. Molecules. 2018;23(12):3301.

Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13:148.

Loizou E, Mayhew DJ, Martlew V, Murthy BVS. Implications of deranged activated partial thromboplastin time for anaesthesia and surgery. Anaesthesia. 2018;73:1557-63.

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-75.

Mahiout S, Linden J, Esteban J, Sanchez-Perez I, Sankari S, Pettersson L, et al. Toxicological characterisation of two novel selective aryl hydrocarbon receptor modulators in Sprague-Dawley rats. Toxicol Appl Pharmacol. 2017;326:54-65.

Martins E, Silva V, Lemos A, Palmeira A, Puthongking P, Sousa E, et al. Newly synthesized oxygenated xanthones as potential P-glycoprotein activators: in vitro, ex vivo, and in silico studies. Molecules. 2019;4(4):E707.

Paiva AM, Pinto MM, Sousa E. A century of thioxanthones: through synthesis and biological applications. Curr Med Chem. 2013;20:2438-57.

Palmeira A, Vasconcelos MH, Paiva A, Fernandes MX, Pinto M, Sousa E. Dual inhibitors of P-glycoprotein and tumor cell growth: (re)discovering thioxanthones. Biochem Pharmacol. 2012;83:57-68.

Parker GA, Papenfuss TL. Immune system. In: Parker G, Picut C (eds): Atlas of histology of the juvenile rat (pp 293-300). Cambridge, MA: Academic Press, 2016.

Pontes H, Duarte JA, de Pinho PG, Soares ME, Fernandes E, Dinis-Oliveira RJ, et al. Chronic exposure to ethanol exacerbates MDMA-induced hyperthermia and exposes liver to severe MDMA-induced toxicity in CD1 mice. Toxicology. 2008;252:64-71.

Raval SH, Joshi DV, Patel BJ, Patel PG, Patel P. Extramedullary haematopoiesis in spleen of Wistar rat: A case report. Indian J Vet Pathol. 2014;38:131-2.

Rossato LG, Costa VM, Dallegrave E, Arbo M, Dinis-Oliveira RJ, Santos-Silva A, et al. Cumulative mitoxantrone-induced haematological and hepatic adverse effects in a subchronic in vivo study. Basic Clin Pharmacol Toxicol. 2014a;114:254-62.

Rossato LG, Costa VM, Dallegrave E, Arbo M, Silva R, Ferreira R, et al. Mitochondrial cumulative damage induced by mitoxantrone: late onset cardiac energetic impairment. Cardiovasc Toxicol. 2014b;14:30-40.

Seibert J, Bodie K, Weber S, Bury D, Kron M, Blaich G. Comparison of haematology, coagulation and clinical chemistry parameters in blood samples from the sublingual vein and vena cava in Sprague-Dawley rats. Lab Anim. 2010;44:344-51.

Shi S, Yao L, Guo K, Wang X, Wang Q, Li W. Hepatocellular toxicity of oxalicumone A via oxidative stress injury and mitochondrial dysfunction in healthy human liver cells. Mol Med Rep. 2018;17:743-52.

Silva R, Carmo H, Dinis-Oliveira R, Cordeiro-da-Silva A, Lima SC, Carvalho F, et al. In vitro study of P-glycoprotein induction as an antidotal pathway to prevent cytotoxicity in Caco-2 cells. Arch Toxicol. 2011;85:315-26.

Silva R, Carmo H, Vilas-Boas V, de Pinho PG, Dinis-Oliveira RJ, Carvalho F, et al. Doxorubicin decreases paraquat accumulation and toxicity in Caco-2 cells. Toxicol Lett. 2013;217:34-41.

Silva R, Sousa E, Carmo H, Palmeira A, Barbosa DJ, Gameiro M, et al. Induction and activation of P-glycoprotein by dihydroxylated xanthones protect against the cytotoxicity of the P-glycoprotein substrate paraquat. Arch Toxicol. 2014;88:937-51.

Silva R, Palmeira A, Carmo H, Barbosa DJ, Gameiro M, Gomes A, et al. P-glycoprotein induction in Caco-2 cells by newly synthetized thioxanthones prevents paraquat cytotoxicity. Arch Toxicol. 2015a;89:1783-800.

Silva R, Vilas-Boas V, Carmo H, Dinis-Oliveira RJ, Carvalho F, de Lourdes Bastos M, et al. Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy. Pharmacol Ther. 2015b;149:1-123.
Slater TF, Delaney VB. Liver adenosine triphosphate content and bile flow rate in the rat. Biochem J. 1970; 116:303-8.

Tabata H, Nakamura S, Matsuzawa T. Some species differences in the false prolongation of prothrombin times and activated partial thromboplastin times in toxicology. Comp Haematol Int. 1995;5:140-4.

Takahashi S, Hirai N, Shirai M, Ito K, Asai F. Comparison of the blood coagulation profiles of ferrets and rats. J Vet Med Sci. 2011;73:953–6.

Teixeira-Gomes A, Costa VM, Feio-Azevedo R, Duarte JA, Duarte-Araujo M, Fernandes E, et al. "Ecstasy" toxicity to adolescent rats following an acute low binge dose. BMC Pharmacol Toxicol. 2016;17(1): 28.

Travlos GS. Normal structure, function, and histology of the bone marrow. Toxicol Pathol. 2006;34:548-65.

Vilas-Boas V, Silva R, Palmeira A, Sousa E, Ferreira LM, Branco PS, et al. Development of novel rifampicin-derived P-glycoprotein activators/inducers. synthesis, in silico analysis and application in the RBE4 cell model, using paraquat as substrate. PLoS One. 2013;8(8):e74425.

Weingand K, Bloom J, Carakostas M, Hall R, Helfrich M, Latimer K, et al. Clinical pathology testing recommendations for nonclinical toxicity and safety studies. AACC-DACC/ASVCP Joint Task Force. Toxicol Pathol. 1992;20:539-43.

Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol. 2013;61:2495-502.

Winter WE, Flax SD, Harris NS. Coagulation testing in the core laboratory. Lab Med. 2017;48:295-313.

Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev. 2000;80:1107-213.

Yao Y, Levings MK, Steiner TS. ATP conditions intestinal epithelial cells to an inflammatory state that promotes components of DC maturation. Eur J Immunol. 2012;42:3310-21.